Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 12/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.31 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.31 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6378124 | 0.84 | PTPN5 (0.40) | CYP1A2CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL15353276 | 0.80 | — | — | |
| SCHEMBL349000 | 0.72 | — | — | |
| SCHEMBL2961646 | 0.72 | TSHR (0.31) | CYP3A4TSHRSLC22A12PDK2ALDH1A1 | |
| SCHEMBL81364 | 0.70 | — | — | |
| SCHEMBL82438 | 0.70 | TDP1 (0.34) | ALDH1A1 | |
| SCHEMBL5314612 | 0.70 | CYP3A4 (0.41) | CYP3A4TSHRALDH1A1 | |
| SCHEMBL328971 | 0.70 | TSHR (0.39) | CYP1A2CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL979387 | 0.68 | — | — | |
| SCHEMBL349389 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240091303-A1 | BIOMARKER-BASED TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND DIABETIC KIDNEY DISEASE | GOLDFINCH BIO, INC. | 2024-03-21 | — | — | US | claimed |
| EP-3852533-B1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO INC (US) | 2024-02-28 | — | — | EP | claimed |
| WO-2023178130-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-09-21 | — | — | WO | claimed |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-05-19 | — | — | US | claimed |
| US-20220024917-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-01-27 | — | — | US | claimed |
| EP-3941475-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2022-01-26 | — | — | EP | claimed |
| CN-113939295-A | Pyridazinones and methods of use thereof | 金翅雀生物公司 | 2022-01-14 | — | — | CN | claimed |
| EP-3852533-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2021-07-28 | — | — | EP | claimed |
| US-11046690-B2 | Pyridazinones and methods of use thereof | GOLDFINCH BIO, INC. (US) | 2021-06-29 | — | — | US | claimed |
| CN-112911935-A | Pyridazinones and methods of use thereof | 金翅雀生物公司 | 2021-06-04 | — | — | CN | claimed |
| WO-2021067946-A1 | BIOMARKER-BASED TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND DIABETIC KIDNEY DISEASE | GOLDFINCH BIO, INC. (US) | 2021-04-08 | — | — | WO | claimed |
| WO-2020191056-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2020-09-24 | — | — | WO | claimed |
| US-20200283437-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2020-09-10 | — | — | US | claimed |
| US-20200102301-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2020-04-02 | — | — | US | claimed |
| WO-2020061162-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2020-03-26 | — | — | WO | claimed |
| EP-1871379-A2 | CYANOARYLAMINES | Smithkline Beecham Corporation (US) | 2008-01-02 | — | — | EP | claimed |
| CN-1980891-A | Indole, benzofuran and benzothiophene derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2007-06-13 | — | — | CN | claimed |
| WO-2006113552-A2 | CYANOARYLAMINES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-26 | — | — | WO | claimed |
| US-20240091303-A1 | BIOMARKER-BASED TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND DIABETIC KIDNEY DISEASE | GOLDFINCH BIO, INC. | 2024-03-21 | — | — | US | disclosed |
| WO-2000017157-A1 | OPTICALLY ACTIVE SUBSTITUTED N-ARYL-O-ARYLOXYALKYL-CARBAMATES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024917-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | ATP6V1B1, GLS, REN | CYP1A2 66/4885CYP3A4 127/4885CYP2C9 137/4885 |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GLS, ATP6V1B1, PDXK | CYP1A2 104/4885CYP3A4 353/4885CYP2C9 643/4885 |
| US-20240091303-A1 | BIOMARKER-BASED TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND DIABETIC KIDNEY DISEASE | TRPC5, REN, SLC5A1 | CYP1A2 4831/4885CYP3A4 4778/4885CYP2C9 4729/4885 |
| US-20200102301-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | ATP6V1B1, GLS, REN | CYP1A2 66/4885CYP3A4 127/4885CYP2C9 137/4885 |
| US-11046690-B2 | Pyridazinones and methods of use thereof | ATP6V1B1, GLS, REN | CYP1A2 66/4885CYP3A4 127/4885CYP2C9 137/4885 |
| US-20200283437-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | ATP6V1B1, GLS, REN | CYP1A2 66/4885CYP3A4 127/4885CYP2C9 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.